Clear and non ambiguous positive outcome would have been a good start. The management have seemingly put a lot of effort into this meeting and emphasised the importance of it numerous times. In fact the meeting was originally slated for June but was delayed. I for one was disappointed that the primary efficacy end point was not agreed on at the meeting. The market sentiment was already negative towards Neuren and I was hoping the management was able to ace this one. Unlike Daybue sales, this is well within their control
NEU chart, page-1936
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |